Filtered By:
Drug: Taxotere
Countries: USA Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 26 results found since Jan 2013.
Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data
This study aimed to generate real-world evidence on treatment patterns, clinical outcomes, health care resource utilization (HCRU), and costs among older patients with metastatic castration-resistant PC (mCRPC).MATERIALS AND METHODS: A claims algorithm based on treatments expected for mCRPC was used to identify men ≥65 years old with mCRPC in the SEER-Medicare data between 2007 and 2019. The index date was defined as the date of the start of first-line therapy (1L). Treatment patterns and all-cause and PC-specific HCRU and costs were measured in the 12 months preindex period and the postindex follow-up period. Time to ne...
Source: Clinical Prostate Cancer - May 29, 2023 Category: Cancer & Oncology Authors: Umang Swami Himani Aggarwal Mo Zhou Shan Jiang Jeri Kim Weiyan Li Fran çois Laliberté Bruno Emond Neeraj Agarwal Source Type: research
The Association between Taxane Use and Lacrimal Disorders
CONCLUSIONS: The growing body of epidemiologic, clinical, and pathophysiologic research supports the case that docetaxel leads to adverse lacrimal events in certain patients and should be taken into consideration when oncologists consider docetaxel vs. paclitaxel.PMID:37232564 | DOI:10.1080/02713683.2023.2219041
Source: Current Eye Research - May 26, 2023 Category: Opthalmology Authors: Gerald McGwin Tucker Contorno Matthew G Vicinanzo Cynthia Owsley Source Type: research
Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study
CONCLUSIONS: These findings suggest that physicians consider mCSPC treatment history when making first-line treatment decisions in mCRPC. Further studies are needed to better understand optimal treatment sequencing, especially as new treatments emerge.PMID:37014097 | DOI:10.1093/oncolo/oyad046
Source: The Oncologist - April 4, 2023 Category: Cancer & Oncology Authors: Pedro C Barata Andrea Leith Amanda Ribbands Rachel Montgomery Matthew Last Bhakti Arondekar Jasmina Ivanova Alexander Niyazov Source Type: research
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer
CONCLUSION: In this large, multicenter retrospective chart review of patients with KRAS G12C mutant NSCLC we observed a relatively short median rwPFS of 4.6 months among 10 patients with KRAS G12C mutant NSCLC treated with docetaxel with or without ramucirumab in the second-line setting, which aligns with the recently reported CodeBreak 200 dataset.PMID:36841727 | DOI:10.1016/j.cllc.2023.01.009
Source: Clinical Lung Cancer - February 25, 2023 Category: Cancer & Oncology Authors: Wade T Iams Meridith L Balbach Sharon Phillips Adrian Sacher Christine Bestvina Vamsidhar Velcheti Xiao Wang Melina E Marmarelis Nan Sethakorn Ticiana Leal Paul E Sackstein Chul Kim Md Andrew Robinson Kathan Mehta Robert Hsu Jorge Nieva Tejas Patil D Ross Source Type: research
Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer
CONCLUSION: We conclude that elevated baseline basophils and BLR are associated with worse clinical outcomes in mHSPC. Although results require further validation, BLR is a potential prognostic biomarker.PMID:35466038 | DOI:10.1016/j.urolonc.2022.03.016
Source: Urologic Oncology - April 25, 2022 Category: Urology & Nephrology Authors: Agreen Hadadi Katherine Er Smith Limeng Wan Jacqueline R Brown Greta Russler Lauren Yantorni Sarah Caulfield Jennifer Lafollette Melvin Moore Omer Kucuk Bradley Carthon Bassel Nazha Yuan Liu Mehmet A Bilen Source Type: research
Cost-effectiveness of nivolumab in patients with NSCLC in the United States
CONCLUSIONS: Nivolumab is likely to be cost-effective for the treatment of patients with advanced NSCLC following platinum-based chemotherapy in the United States.PMID:34460179 | DOI:10.37765/ajmc.2021.88726
Source: The American Journal of Managed Care - August 30, 2021 Category: Health Management Authors: Mohammad A Chaudhary Solomon J Lubinga Caitlin Smare Nadine Hertel John R Penrod Source Type: research
Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study
CONCLUSIONS: This real-world study provides novel data on patients treated with docetaxel post-NHAs in a mCRPC setting and highlights the critical unmet need for developing more effective treatment options in this population.PMID:34373223 | DOI:10.1016/j.clgc.2021.07.009
Source: Clinical Prostate Cancer - August 10, 2021 Category: Cancer & Oncology Authors: Neal D Shore Raluca Ionescu-Ittu Fran çois Laliberté Lingfeng Yang Dominique Lejeune Louise Yu Mei Sheng Duh Malena Mahendran Jeri Kim Sameer R Ghate Source Type: research
